This challenge notwithstanding, the potential incorporation of the tumor-associated antigen RHAMM into monocyte-derived dendritic cells (mo-DCs) through mRNA electroporation for cancer immunotherapy has been explored, revealing that classical mo-DCs already naturally express and present RHAMM at levels sufficient to activate RHAMM-specific T cells in AML patients, suggesting that existing immunotherapy approaches may already inadvertently target RHAMM [115]. The gene discussed is HMMR; the disease is acute myeloid leukemia.